Adlai Nortye (ANL) Competitors $1.98 +0.14 (+7.34%) Closing price 05/1/2025 03:41 PM EasternExtended Trading$1.98 0.00 (0.00%) As of 05/1/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Adlai Nortye (NASDAQ:ANL) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations. Do insiders & institutionals have more ownership in ANL or ATAI? 35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer ANL or ATAI? In the previous week, Adlai Nortye had 2 more articles in the media than Atai Life Sciences. MarketBeat recorded 3 mentions for Adlai Nortye and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Adlai Nortye's score of 1.58 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Very Positive Atai Life Sciences Very Positive Does the MarketBeat Community believe in ANL or ATAI? Atai Life Sciences received 326 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 66.53% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformAdlai NortyeOutperform Votes8100.00% Underperform VotesNo VotesAtai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Do analysts recommend ANL or ATAI? Adlai Nortye presently has a consensus target price of $9.00, suggesting a potential upside of 355.70%. Atai Life Sciences has a consensus target price of $10.50, suggesting a potential upside of 614.29%. Given Atai Life Sciences' higher possible upside, analysts clearly believe Atai Life Sciences is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ANL or ATAI? Adlai Nortye has a beta of -1.03, meaning that its share price is 203% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Which has stronger earnings & valuation, ANL or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M14.58-$104.87MN/AN/AAtai Life Sciences$308K953.57-$40.22M-$0.93-1.58 Is ANL or ATAI more profitable? Adlai Nortye's return on equity of 0.00% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Atai Life Sciences N/A -65.75%-52.71% SummaryAtai Life Sciences beats Adlai Nortye on 8 of the 14 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.88M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales14.58241.49397.62103.30Price / CashN/A65.8538.1834.62Price / BookN/A6.486.734.25Net Income-$104.87M$143.41M$3.22B$248.18M7 Day Performance-1.20%2.58%1.38%1.03%1 Month Performance-5.50%5.00%2.79%2.70%1 Year Performance-84.83%-3.72%15.41%4.05% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye2.6187 of 5 stars$1.98+7.3%$9.00+355.7%-84.8%$72.88M$5M0.00127Short Interest ↓News CoveragePositive NewsGap UpATAIAtai Life Sciences2.6854 of 5 stars$1.42-3.4%$10.50+639.4%-28.3%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4144 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading VolumeAURAAura Biosciences2.3284 of 5 stars$5.57+3.9%$22.75+308.4%-20.7%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑News CoverageGap DownCYRXCryoport2.3795 of 5 stars$5.52-0.5%$11.67+111.4%-67.5%$275.50M$228.39M-1.631,020Upcoming EarningsGLUEMonte Rosa Therapeutics1.9766 of 5 stars$4.46-2.0%$15.50+247.5%-17.5%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑News CoveragePHATPhathom Pharmaceuticals4.0415 of 5 stars$3.90-3.2%$21.83+459.8%-63.7%$271.58M$55.25M-0.69110News CoveragePositive NewsGap DownRNACCartesian Therapeutics1.9573 of 5 stars$10.34-1.5%$42.14+307.6%-45.8%$267.88M$38.91M-0.2064Upcoming EarningsTSVT2seventy bio1.7536 of 5 stars$4.99+0.2%$5.60+12.2%+8.3%$261.17M$37.86M-2.68440Short Interest ↑News CoverageMNPRMonopar Therapeutics2.8832 of 5 stars$42.71+7.9%$55.33+29.6%+1,227.7%$261.09MN/A-21.6810Upcoming EarningsGap DownSEPNSepterna2.248 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies Atai Life Sciences Alternatives Palvella Therapeutics Alternatives Aura Biosciences Alternatives Cryoport Alternatives Monte Rosa Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives 2seventy bio Alternatives Monopar Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANL Stock Free ANL Stock Alerts